Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Malaria transmission blocking compounds: a patent review53
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities46
Update on mGlu4 modulator patents: 2017 to present44
Recent developments of agents targeting Vibrio cholerae : patents and literature data36
FAK inhibitors in cancer, a patent review – an update on progress36
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature35
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)32
The role of patent analysis in target selection31
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)30
Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision30
Mucormycosis medications: a patent review30
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)29
Caspase inhibitors: a review on recently patented compounds (2016–2023)28
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present27
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)27
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review25
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201324
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)24
An updated patent review of AKT inhibitors (2020 – present)23
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review21
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)21
PDE1 inhibitors: a review of the recent patent literature (2008-present)21
A patent review of MAPK inhibitors (2018 – present)21
Antiprotozoal drugs: challenges and opportunities20
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)20
Inhibition of GTPase KRAS G12D : a review of patent literature20
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202320
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)19
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)19
Small-molecule RNA ligands: a patent review (2018–2024)18
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)17
An updated patent review on PD-1/PD-L1 antagonists (2022-present)17
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)17
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders17
An updated patent review of MALT1 inhibitors (2021–present)17
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature16
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)16
A patent and literature review of CDK12 inhibitors15
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)15
Dopamine D3 receptor ligands: a patent review (2014–2020)15
An updated patent review of EZH2 inhibitors (2024–present)14
Antimalarial drugs: what’s new in the patents?14
Biofilm and bacterial membrane vesicles: recent advances14
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)13
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
Ferroportin-inhibitor salt: patent evaluation WO201819297313
Are patents important indicators of innovation for Chagas disease treatment?13
A patent review of NLRP3 inhibitors to treat autoimmune diseases13
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
The patent review of the biological activity of tropane containing compounds12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
An updated patent review of Akt inhibitors (2016-present)11
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
Correction11
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
An updated patent review of TRPA1 antagonists (2020 – present)11
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)10
Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages10
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
A patent review of selective CDK9 inhibitors in treating cancer10
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)10
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)10
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)9
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)9
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)9
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)9
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)9
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress9
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)9
A patent review of CXCR7 modulators (2019-present)9
A patent review of BRD4 inhibitors (2020–present)9
A patent review of mTOR inhibitors for cancer therapy (2011–2020)9
Patent landscape of small molecule inhibitors of METTL3 (2020-present)8
A patent review of glutaminyl cyclase inhibitors (2004–present)8
Therapeutic cysteine protease inhibitors: a patent review (2018–present)8
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)8
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid8
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
A patent perspective of antiangiogenic agents8
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20237
Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020)7
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present)7
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update7
An updated patent review on monoamine oxidase (MAO) inhibitors7
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents7
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective6
Recent advances in the development of STING inhibitors: an updated patent review6
Pitfalls in patenting academic CAR-T cells therapy6
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)6
Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 20216
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)6
An updated patent review of Mcl-1 inhibitors (2020–2022)6
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)6
A patent review of xanthine oxidase inhibitors (2021–present)6
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)6
Proteasome inhibitors as anticancer agents5
An updated patent review of BRD4 degraders5
Natural products as a source of new anticancer chemotypes5
Recent updates on Wnt signaling modulators: a patent review (2014-2020)5
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature5
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present5
An updated patent review of stimulator of interferon genes agonists (2021 – present)5
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)5
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)5
A review of the patent literature surrounding TRPV1 modulators5
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)5
Anticancer drugs: where are we now?5
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)5
An updated patent review of glutaminase inhibitors (2019–2022)5
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)4
Menin-MLL protein-protein interaction inhibitors: a patent review (2014–2021)4
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)4
A patent review of adenosine A2Breceptor antagonists (2016-present)4
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections4
Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021)4
Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)4
A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)4
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)4
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)4
PIM kinase inhibitors: an updated patent review (2016-present)4
CBL-B – An upcoming immune-oncology target4
Update on JNK inhibitor patents: 2015 to present4
Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)4
Targeting the TGF-β signaling pathway for fibrosis therapy: a patent review (2015–2020)4
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)4
BET inhibitors: an updated patent review (2018–2021)4
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326154
Targeting the TGF-β signaling pathway: an updated patent review (2021–present)4
CDC7 kinase inhibitors: a survey of recent patent literature (2017–2022)4
MEK inhibitors in oncology: a patent review and update (2016 – present)4
0.48255586624146